The news: AstraZeneca and Bristol Myers Squibb have held early stage talks about a potential merger that would create a roughly $400 billion company. If completed, the deal would rank among the largest pharma mergers in history. AstraZeneca's US-listed shares fell 8% by midday Monday, while Bristol Myers Squibb shares gave up an early 4% premarket gain to trade down 1%.

Why it matters: A combined AstraZeneca and Bristol Myers Squibb would create one of the world's largest pharma companies, but investors are questioning why AstraZeneca would pursue the deal given its strong growth trajectory.

The clearest strategic rationale for the merger is within oncology. Together, AstraZeneca and Bristol Myers Squibb could create the industry's largest cancer portfolio. AstraZeneca's oncology business, led by Tagrisso, Imfinzi, Lynparza, and Calquence, accounted for 46% of first-half revenue, while Bristol Myers Squibb brings blockbuster cancer drugs including Opdivo, along with Revlimid and Yervoy. The two pharmas’ research pipelines are also complementary, with AstraZeneca stronger in solid tumors and Bristol Myers Squibb in blood cancers and cell therapy, according to Jefferies analysts.

For AstraZeneca, the initial market reaction has been negative, likely because the deal doesn't appear necessary to accelerate its growth. The company is on track to launch 20 new drugs by 2030 and reach $80 billion in annual revenue. CEO Pascal Soriot told investors on last week's Q2 earnings call that AstraZeneca doesn't need mergers and acquisitions to meet those goals. While Bristol Myers Squibb would expand AstraZeneca's US footprint, the company already generates about 40% of its revenue in the US and committed another $50 billion to grow its US R&D and manufacturing last year.

For Bristol Myers Squibb, merging with a larger, faster-growing company could help offset looming patent losses for blockbusters Eliquis and Opdivo in 2028. The two drugs generated $14.4 billion and $10.0 billion, respectively, last year and together accounted for about half of Bristol Myers Squibb's $48.2 billion in annual revenue. Significant revenue declines are expected as generic and biosimilar competition enters the market for both drugs.

Implications for pharma companies: The reported merger discussions are still preliminary, but if negotiations continue, the companies would likely face intense antitrust review. Combining two oncology leaders could draw regulatory scrutiny in part because Imfinzi and Opdivo compete across several cancer indications. Jefferies analysts noted additional overlap in cardiovascular disease and immunology, making multiple divestitures a likely condition for approval. That kind of review would be lengthy and costly, raising the complexity of completing a deal and delaying any potential benefits.

Other drugmakers will be watching closely to see how the talks play out as they evaluate their own growth and acquisition strategies. If the deal moves forward, it could renew interest in major pharma mergers and influence how companies think about pursuing transformational acquisitions. But if the talks stall or the deal fails to move forward, it could reinforce the view that even the largest drugmakers are better served by organic growth, targeted acquisitions, and partnerships than by transformational mergers.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.